

Identification of secondary prevention patients eligible for PCSK9 inhibitors therapy according to the routine clinical practice in Spain

Juan Cosin-Sales, Eduard Sidelnikov, Santiago Villamayor, Miriam Fernández, Sandra Merino-Montero, Alberto Zamora.

- 9,516 ASCVD patients
- 63.9% male
- Mean (SD) age 67.7 (12.5) years
- Mean LDL-C (SD) 117.3 (38.8) mg/dL





The 17.9% of patients who are not treated with a PCSK9i despite being eligible remain at an unnecessarily excess risk of a recurrent CV event

* Myocardial infarction, unstable angina, ischaemic stroke, transient ischaemic attack, or peripheral artery disease patients with ≥1 LDL-C measurement available in a time period ≥3 months after index date.

** According to the reimbursement conditions applicable in Spain (Therapeutic Positioning Report).

PEER-REVIEWED FEATURE

Adis

OPEN ACCESS

The graphical abstract represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online. © The authors, CC-BY-NC 2022